BACKGROUND: Gastroesophageal reflux disease is a risk factor for the development of Barrett's esophagus and esophageal adenocarcinoma. The effect of antireflux therapy on the incidence of esophageal adenocarcinoma is unknown. Acid exposure in vitro induces hyperproliferation via a cyclooxygenase-2 (COX-2) dependent mechanism. Epidemiologic and animal studies suggest that COX inhibitors decrease the incidence of esophageal adenocarcinoma. AIM: To study the differential effect of complete compared with incomplete acid suppression on proliferation, apoptosis, and COX-2. PATIENTS AND METHODS: Fifty-one patients with Barrett's esophagus who underwent pH monitoring were divided into two groups according to their DeMeester score: 32 acid-suppressed patients (group 1) and 19 patients with abnormally high acid exposure (group 2). Slides from biopsies taken 3 months before and 4 and 12 months after pH monitoring were stained for Mcm2, COX-2, c-myc, and cleaved caspase-3 (marker of apoptosis). RESULTS: There was no evidence of a difference between the two groups in terms of age, gender ratio, medication, dysplasia status, and the expression levels of any marker before pH monitoring. In group 1, Mcm2 expression decreased in the luminal surface and throughout the tissue 12 months after monitoring when compared with the two previous time points (P < 0.05). The levels of COX-2 increased overtime (P < 0.01 in group 1, not significant in group 2). There was no correlation between Mcm2 and COX-2 expression. Acid suppression had no effect on c-myc or apoptosis. CONCLUSION: Long-term acid suppression reduces proliferation in Barrett's esophagus samples but has no advantageous effect on c-myc, apoptosis, or COX-2.
BACKGROUND: Gastroesophageal reflux disease is a risk factor for the development of Barrett's esophagus and esophageal adenocarcinoma. The effect of antireflux therapy on the incidence of esophageal adenocarcinoma is unknown. Acid exposure in vitro induces hyperproliferation via a cyclooxygenase-2 (COX-2) dependent mechanism. Epidemiologic and animal studies suggest that COX inhibitors decrease the incidence of esophageal adenocarcinoma. AIM: To study the differential effect of complete compared with incomplete acid suppression on proliferation, apoptosis, and COX-2. PATIENTS AND METHODS: Fifty-one patients with Barrett's esophagus who underwent pH monitoring were divided into two groups according to their DeMeester score: 32 acid-suppressed patients (group 1) and 19 patients with abnormally high acid exposure (group 2). Slides from biopsies taken 3 months before and 4 and 12 months after pH monitoring were stained for Mcm2, COX-2, c-myc, and cleaved caspase-3 (marker of apoptosis). RESULTS: There was no evidence of a difference between the two groups in terms of age, gender ratio, medication, dysplasia status, and the expression levels of any marker before pH monitoring. In group 1, Mcm2 expression decreased in the luminal surface and throughout the tissue 12 months after monitoring when compared with the two previous time points (P < 0.05). The levels of COX-2 increased overtime (P < 0.01 in group 1, not significant in group 2). There was no correlation between Mcm2 and COX-2 expression. Acid suppression had no effect on c-myc or apoptosis. CONCLUSION: Long-term acid suppression reduces proliferation in Barrett's esophagus samples but has no advantageous effect on c-myc, apoptosis, or COX-2.
Authors: Bruce D Greenwald; Charles J Lightdale; Julian A Abrams; John D Horwhat; Ram Chuttani; Srinadh Komanduri; Melissa P Upton; Henry D Appelman; Helen M Shields; Nicholas J Shaheen; Stephen J Sontag Journal: Ann N Y Acad Sci Date: 2011-09 Impact factor: 5.691
Authors: Lisa A Lai; Rumen Kostadinov; Michael T Barrett; Daniel A Peiffer; Dimitry Pokholok; Robert Odze; Carissa A Sanchez; Carlo C Maley; Brian J Reid; Kevin L Gunderson; Peter S Rabinovitch Journal: Mol Cancer Res Date: 2010-07-20 Impact factor: 5.852
Authors: Jing Hao; Bin Zhang; Ba Liu; Maojung Lee; Xingpei Hao; Kenneth R Reuhl; Xiaoxin Chen; Chung S Yang Journal: Int J Cancer Date: 2009-03-15 Impact factor: 7.396
Authors: Zehra B Omer; Ashwin N Ananthakrishnan; Kevin J Nattinger; Elisabeth B Cole; Jesse J Lin; Chung Yin Kong; Chin Hur Journal: Clin Gastroenterol Hepatol Date: 2012-03-15 Impact factor: 11.382
Authors: Bhaskar Banerjee; Nicholas J Shaheen; Jessica A Martinez; Chiu-Hsieh Hsu; Eugene Trowers; Blake A Gibson; Gary Della'Zanna; Ellen Richmond; H-H Sherry Chow Journal: Cancer Prev Res (Phila) Date: 2016-02-23
Authors: Judy S Wang; Andrea Varro; Charles J Lightdale; Nantaporn Lertkowit; Kristen N Slack; Michael L Fingerhood; Wei Yann Tsai; Timothy C Wang; Julian A Abrams Journal: Am J Gastroenterol Date: 2009-11-10 Impact factor: 10.864
Authors: Dennis L Chao; Carissa A Sanchez; Patricia C Galipeau; Patricia L Blount; Thomas G Paulson; David S Cowan; Kamran Ayub; Robert D Odze; Peter S Rabinovitch; Brian J Reid Journal: Clin Cancer Res Date: 2008-11-01 Impact factor: 12.531
Authors: J Nwachokor; O Tawfik; M Danley; S Mathur; J House; P Sharma; L K Christenson; A Bansal Journal: Dis Esophagus Date: 2017-09-01 Impact factor: 3.429